Evidence map›Paper›PMID 42098069›Full record

ArticleCell death discovery2026

RHOV couples EMT-associated plasticity to cytoskeletal execution of invasion and metastasis.

Qi Wang, Yaru Zhao, Shenghui Huang, Haiyan Fu, Chiara Reina, Alexandra Aicher, Jiajia Tang, Christopher Heeschen

Abstract read
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qi Wang *Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yaru Zhao *Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shenghui HuangDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Haiyan FuDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Chiara ReinaPancreatic Cancer Heterogeneity, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Turin, Italy.
Alexandra AicherPrecision Immunotherapy, Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
Jiajia TangCenter for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China. jiajia.tang@shsmu.edu.cn.ORCID http://orcid.org/0000-0002-7775-827X
Christopher HeeschenPancreatic Cancer Heterogeneity, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Turin, Italy. christopher.heeschen@ircc.it.ORCID http://orcid.org/0000-0002-1158-8554

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Euratom (H2020 Euratom Research and Training Programme 2014-2018) CAM-PaCEC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) Pa-CSC 233460Foundation of Shanghai Municipal Commission of Health and Family Planning (Shanghai Municipal Commission of Health and Family Planning Foundation) 2021-01-07-00-02-E00090Ministero della Salute (Ministry of Health, Italy) 2017 PTCRC-Intra 2020Ministero della Salute (Ministry of Health, Italy) 2018 ADVANCEMinistero della Salute (Ministry of Health, Italy) 2022 CARESSMinistero della Salute (Ministry of Health, Italy) Ricerca Corrente 2025National Natural Science Foundation of China (National Science Foundation of China) 82250710179National Natural Science Foundation of China (National Science Foundation of China) 82503485
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by early invasion and rapid metastatic dissemination, yet the cytoskeletal mechanisms that enable these aggressive behaviors remain incompletely defined. Here, we identify the atypical Rho GTPase RHOV as a critical regulator of invasive progression and metastasis in PDAC. Integrated analyses of independent patient cohorts, patient-derived models, and single-cell transcriptomic datasets revealed that RHOV is selectively overexpressed in malignant epithelial cells, with high RHOV expression correlating with advanced disease stage and poor patient survival. Genetic suppression or deletion of RHOV impaired PDAC cell invasion, migration, clonogenic growth, and context-dependent sphere formation in vitro, while reducing tumor-initiating capacity and metastatic colonization in vivo. Mechanistically, RHOV maintains BRK1-dependent WAVE regulatory complex integrity to sustain lamellipodia formation and invasive motility. Loss of RHOV uncoupled EMT-associated transcriptional programs from cytoskeletal execution of invasion, resulting in compensatory EMT gene expression without restoration of invasive behavior. Re-expression of BRK1 rescued invasion defects following RHOV inhibition. Together, these findings identify RHOV as an executional dependency that enables PDAC invasiveness by linking transcriptional plasticity to actin-based motility.

Identifiers

PMID42098069
PMCPMC13319111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.